AZ-AXWAY
30.11.2022 08:01:52 CET | Business Wire | Press release
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, today announced new data from its inaugural 2022 Open Everything Strategy Survey Report. Polling nearly 1,000 IT leaders, architects, and developers about their digital strategies and top concerns, the survey found nearly 40% of organizations are in the process of adopting a new hybrid approach for their IT infrastructure. The transformation comes as 68% of respondents cite their fears about API sprawl.
The survey data reflects responses from those engaged primarily in API development (893) and managed file transfer (MFT) services (102). Ensuring data security and controlling API sprawl were top concerns, with over two-thirds (68%) worrying about complexity due to sprawl and almost half (48%) of respondents ranking “increased security challenges” as their single greatest concern with API growth. Respondents again cited security as far and away the most important criteria when creating an API (30% among API respondents) and when setting up a new MFT service (48% among MFT respondents).
“Enterprises are in the thick of digital transformation and accompanying cloud and data migrations have made it possible to free up data so it can be exchanged, reused and remixed to fuel innovation and business growth. But that’s messy,” said Vince Padua, Chief Innovation and Technology Officer at Axway. “It brings complexity and security challenges that must be answered by using truly universal API management—that bridges the gap between API development and consumption and opens everything, lines of business and innovation, while building on and out from heritage infrastructure.”
The survey results indicate that budgets for API management have increased over the past two years and that security is top of mind as companies begin to unlock the full value of their data to create new digital experiences, markets and opportunities for revenue. Half of those surveyed reported modestly elevated API management budgets, with about 34% of respondents seeing increases up to 25%. Less than 20% of respondents saw budget decreases.
Drilling down further into security strategy and the impending skills gap
Digging deeper, the survey found that a significant majority, 59%, employ user authentication as a top strategy to secure APIs, and almost two-thirds of the API respondents (61%) said data encryption can help them personally feel their data is more secure. They also cited developing a more holistic approach to security as the number one strategy for protecting personal data.
When a member logs into our online channels or walks into one of our branches, we want to personalize their experience in real time. To achieve this, we targeted a high-performance API integration layer,” said Ravi Peru, Chief Information Officer at Community America Credit Union.
"When you have more than 50 products, handling integration in an agile way is very important," added Peru. "With Axway, we can interface with anything and move data between any internal systems we want. That would be really slow with point-to-point integration, but Axway makes it quick and easy."
Security factors into cloud strategy as well. Among the most significant challenges inhibiting cloud strategy, according to respondents, are:
- 53% – Dealing with different security requirements for regional instances of cloud infra
- 55% – Tracking and controlling the flow of personal data into and through the cloud
One of the most alarming, but not entirely surprising data points, deals with concerns about talent: 86% of API respondents fear an expertise gap in the coming years, where companies will not have the skilled software and IT infrastructure talent they need to innovate.
Click here to see the full report.
Survey Methodology
The 2022 Open Everything Strategy Survey was conducted between July 21 and August 16 of 2022 among two similar, but divided subsets of respondents: API development and MFT integration professionals. Axway engaged in direct email outreach among its contacts with opt-in email addresses, and received nearly 1,000 responses, including 893 from those in API development and 102 in MFT services, from various locations throughout the world.
About Axway
Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
